Prophylactic skin-sparing mastectomy (SSM) is associated with major breast cancer risk reduction in high-risk patients. In prophylactic nipple-sparing mastectomy (NSM) it is unknown how many terminal duct lobular units (TDLUs) remain behind the nipple-areola complex (NAC) additionally to those behind the skin flap. Therefore, safety of NSM can be doubted. We compared amounts of TDLUs behind the NAC as compared with the skin. In prophylactic SSM and conventional therapeutic mastectomy patients, the NAC and an adjacent skin island (SI) were resected as if it were an NSM. NAC and SI were serially sectioned perpendicularly to the skin and analyzed for the amount of TDLUs present. Slides of NAC and SI were scanned, and slide surface areas (cm 2 ) were measured. TDLUs/ cm 2 in NAC versus SI specimen, representing TDLU density, were analyzed pairwise. In total, 105 NACs and SIs of 90 women were analyzed. Sixty-four NACs (61%) versus 25 SIs (24%) contained Z1 TDLUs. Median TDLU density was higher in NAC specimens (0.2 TDLUs/cm 2 ) as compared with SI specimens (0.0 TDLUs/cm 2 ; P < 0.01). Independent risk factors for the presence of TDLUs in the NAC specimen were younger age and parity (vs. nulliparity). The finding of higher TDLU density behind the NAC as compared with the skin flap suggests that sparing the NAC in prophylactic NSM in high-risk patients possibly may increase postoperative breast cancer risk as compared with prophylactic SSM. Studies with long-term follow-up after NSM are warranted to estimate the level of residual risk.
BACKGROUND BRCA1/2 mutation carriers have a cumulative lifetime breast cancer risk of 55% to 85% by the age of 70. [1] [2] [3] [4] [5] As an alternative to surveillance, BRCA1/2 mutation carriers and other high-risk patients may choose to undergo prophylactic bilateral mastectomy and breast reconstruction, achieving risk reductions of 90% to 100% after 3 to 13 years of follow-up. [6] [7] [8] [9] [10] To allow for direct breast reconstruction after mastectomy, the technique of skin envelope-preserving mastectomy (skin-sparing mastectomy; SSM) aims to spare the skin of the breast. In SSM, a periareolar incision is used (see supplementary Figs. 1a and b, Supplemental Digital Content 1, http://links.lww.com/PAS/A193, which show a circular (a) and a drop-shaped (b) incision as used in SSM). Breast glandular tissue is excised subcutaneously creating a skin envelope while preserving a thin subcutaneous layer to support skin vascularization. Nipple-papilla and the surrounding pigmented areola (nipple-areola complex; NAC) are removed. In addition, a breast reconstruction is performed. SSM is generally considered oncologically safe for prophylactic and therapeutic indications, although no prospective randomized controlled trials have been conducted. [6] [7] [8] [9] [10] [11] Preservation of the NAC in SSM (nipple-sparing mastectomy; NSM) may further improve cosmetic outcome and patient satisfaction. 12 In NSM, a semicircular incision is used to create a skin envelope as in SSM (see supplementary Fig. 1c , Supplemental Digital Content 1, http://links.lww.com/PAS/A193, which shows a semicircular incision as used in NSM). The NAC is dissected as thin as possible by macroscopically removing all breast glandular tissue while preserving vascularization (see supplementary Fig. 2a , Supplemental Digital Content 2, http://links.lww.com/PAS/A194, which shows intraoperative dissection of the NAC). The nipple-papilla is "cored" by inverting it and excising residual breast glandular tissue (see supplementary Fig. 2b , Supplemental Digital Content 2, http://links.lww.com/PAS/ A194, which illustrates the "coring" of the nipple-papilla). 13 The NAC is then left in situ adherent to the skin envelope. NSM has been reported safe for selected patients with small, peripherally located breast cancers. 14 However, long-term oncologic safety of NSM for breast cancer prophylaxis in BRCA1/2 mutation carriers and other women with high breast cancer risk is still subject to debate. Various authors have found terminal duct lobular units (TDLUs) in and/or closely behind the NAC. [15] [16] [17] TDLUs in the mammary gland are defined as a terminal duct combined with an associated lobule and are known as the origin of invasive breast cancer. 18, 19 Theoretically, any residual TDLUs behind skin or behind NAC may remain a lifelong potential hazard for developing ductal carcinoma in situ or invasive breast cancer. Although SSM is considered a safe risk-reducing option, residual TDLUs have also been found behind skin flaps after SSM. 20 Several studies have reported safety of NSM in high-risk patients, but they lack follow-up. 21, 22 Lifelong follow-up of BRCA1/2 mutation carriers would be necessary to estimate the remaining oncologic risk of any residual breast tissue after prophylactic surgery, particularly NSM. We compared presence and amounts of TDLUs remaining behind the NAC with presence and amounts of TDLUs behind the skin flap, to assess whether NSM would lead to a significant increase in the remaining TDLUs as compared with SSM.
METHODS

Patients
Women 18 years of age or older who underwent conventional mastectomy or SSM for prophylactic or therapeutic indications were eligible. Exclusion criteria were gross abnormalities of the nipple (flat, inverted, retracted, or Paget disease) attributable to nipple involvement of the tumor, a malignancy with radiologic nipple involvement, a malignancy at r1 cm distance to the nipple or skin, a history of radiotherapy of the breast or an earlier operation in the NAC or skin area. Parameters such as age, body mass index (BMI), breast size, menopausal status, parity, history of breast-feeding, and history of chemotherapy were collected from medical files.
The institutional Medical Ethical Board approved the study. According to the Dutch "Code of Conduct" for secondary use of human tissue, the use of excised tissue for research purposes after standard diagnostic procedures is part of the standard treatment agreement in the Netherlands.
Surgical Technique
Oncologic surgeons from 4 centers participated in this study. All of them were experienced in performing NSMs. The participating surgeons were assisted by one of the researchers at their first inclusions to ensure that identical techniques were used ( Fig. 1 ; supplementary Fig. 2 , Supplemental Digital Content 2, http://links.lww.com/PAS/A194). In a conventional mastectomy (non-SSM) or SSM, circles were drawn around the NAC and around an as large as possible periareolar circular skin island (SI) representing the skin flap, which would be spared in SSM or NSM (Fig. 1 ). The periareolar location of the SI was chosen because of the assumed pyramid shape of the breast gland, therefore expecting most TDLUs behind the skin near the NAC. Diameters of NAC and SI were measured before excision. Then the NAC was excised as thin as possible (ie, without compromising blood flow and consequently inducing necrosis; supplementary 
Analysis of TDLUs
NAC and SI specimens were formalin fixed, serially sectioned perpendicularly to the skin into 2-mm-thick slices, paraffin embedded, and entirely submitted for routine hematoxylin and eosin staining ( Fig. 2 ). Microscopic examination was performed by 2 breast pathologists (C.H.M.v.D. and P.J.W.) after obtaining consensus on TDLU definition and specification of anatomic locations. A TDLU was defined as a terminal duct and its associated lobule ( Fig. 3 ), characterized by (1) the presence of a loose intralobular stroma that was different from the surrounding, denser, more collagenized interlobular stroma and (2) the presence of a typical double cell layer confining the lobular acini. 23 TDLUs were counted, and their anatomic locations ("dermis", "breast stroma," or "fat") were noted.
Hematoxylin and eosin slides of NAC and SI specimens were scanned. Surface areas of slides (slide area, cm 2 ) were calculated using Adobe Photoshop. Total TDLU quantities were corrected for the sum of slide areas, representing density of TDLUs in NAC or in SI: TDLU density = TDLUs/Sslide areas (cm 2 ) ( Fig. 2 ).
Statistical Analysis
Differences in amounts of TDLUs in NAC as compared with SI were tested pairwise using the Wilcoxon signed rank test. Binary logistic regression was used for multivariable analysis of factors that may influence the presence of TDLUs in the NAC, including the interaction term age Â menopausal status. Variables with a P-value of <0.1 in univariable analysis were included in the multivariable analysis. All P-values were 2-sided, and a significance level of a = 0.05 was used. The SPSS computer package (version 20.0) was used for statistical analyses.
RESULTS
After 75 unilateral and 30 bilateral mastectomies in 90 women, 105 NACs and SIs were available for analysis. The indication for mastectomy was prophylactic in 31, therapeutic (in situ or invasive carcinoma) in 71, and symptomatic (chronic mastodynia) in 3 cases. Median age at unilateral or bilateral mastectomy was 49 years (range, 26 to 86 y), and 59 women (56%) were postmenopausal ( Table 1 ). In 14 of them, menopause had been induced by bilateral oophorectomy at premenopausal age. Four women had undergone neoadjuvant chemotherapy, 9 women had a history of adjuvant chemotherapy for breast cancer, and 4 women had a history of chemotherapy for another indication.
TDLUs in NAC Specimen and in SI Specimen
Median diameter of the NAC was 4.0 cm (range, 1.2 to 7.0 cm) and that of the SI was 4.0 cm (range, 1.0 to 7.0 cm). In 64 NAC specimens (61%) Z1 TDLUs were found, as compared with 25 SI specimen (24%, P < 0.01). In 21 mastectomies TDLUs were found in both NAC and SI, and in 37 mastectomies TDLUs were found neither in NAC nor in SI. In 43 mastectomies TDLUs were merely found in the NAC, whereas in 4 mastectomies TDLUs were found only in the SI.
Median amount of total TDLUs in the NAC specimen was 2 (range, 0 to 186) versus 0 (range, 0 to 48) in the SI specimen, with a median difference of 1 TDLU (P < 0.01) in paired analysis. Median slide areas were 15.9 cm 2 (range, 3.7 to 40.0 cm 2 ) for NAC and 9.9 cm 2 (range, 0.3 to 57.4 cm 2 ) for SI. With adjustment for slide areas, the TDLU density was 0.2/cm 2 in the NAC (range, 0.0 to 8.5/cm 2 ) versus 0.0/cm 2 (range, 0.0 to 0.5/cm 2 ) in the SI (P < 0.01). Anatomically, in the NACs most TDLUs (95%) were located in breast stroma and only 3% of TDLUs in the fat tissue. In contrast, in the SIs only 33% of TDLUs were located in breast stroma and 66% of TDLUs in the fat tissue. Location of TDLUs in the dermis was rare (2% in NACs and 1% in SIs).
Presence of TDLUs in the NAC
The influence on the presence of TDLUs in the NAC of the variables age, menopausal status, BRCA1/2 mutation status, history of chemotherapy, parity, breastfeeding, BMI, breast size, and participating hospital was assessed by univariable logistic regression analysis (Table 2). Age and BMI were entered as continuous variables. After univariable analysis, the variables age, menopausal status, parity, and breast-feeding and the interaction variable "age Â menopausal status" were entered in the multivariable model. Risk factors for the presence of TDLUs in the NAC were younger age (odds ratio 0.93; 95% confidence interval, 0.89-0.98) and parity (Z1 childbirths as compared with nullipara; odds ratio 7.6; 95% confidence interval, 1.8-32.3).
DISCUSSION
BRCA1/2 mutation carriers have the option to undergo prophylactic bilateral mastectomy and breast reconstruction to reduce breast cancer risk. Sparing the NAC is an alternative to SSM, which is thought to be oncologically safe. To estimate safety of the NAC (and skin)-sparing technique, we assessed the presence and quantities of TDLUs behind the NAC as compared with the skin in women undergoing a prophylactic SSM or a therapeutic mastectomy. We compared the amount of TDLUs behind the NAC and skin that would remain if the NAC and skin had been spared. As NAC and SI were surgically dissected as in NSM, results are clinically applicable. Several studies have reported on TDLUs in the NAC or behind the skin. [15] [16] [17] 20, 24 Reynolds and colleagues found TDLUs in only 24% of examined NACs, compared with 60% of NACs in this series. The NACs were retrieved ex vivo from mastectomy specimens, possibly using more shallow incisions creating thinner NACs as compared with our study with in vivo dissection of the NAC (and SI). 15 Stolier and Wang 16 found TDLUs in 3 of 32 (9%) nipples, and, recently, Kryvenko et al 17 found TDLUs in 17 of 65 (26%) examined nipples. In these 2 studies, however, only the nipple-papilla was examined after transection at its basis. Nipple-basis and areola, possibly containing more TDLUs than the papilla, were not analyzed. One study evaluated 42 skin flaps that would have remained after SSM and that presumably were considerably larger than the SIs in the current study. Consequently, the authors found TDLUs in almost 60% of the skin flaps, in contrast with our study with TDLUs in 22% of SIs. They found that the presence of TDLUs behind the skin flap was associated with a skin flap thicker than 5 mm. 20 In general, differences between our results and the existing literature may partly be explained by differences in dissection methods. In our dissection method, we took the viability of the spared NAC or SI into account, while trying to macroscopically remove all breast tissue. The observation that, microscopically, only 2% of TDLUs in the NAC and 1% in the SI were located in the dermis supports the idea that a thinner dissection minimizes the remaining TDLUs.
Risk factors for the presence of TDLUs were a younger age and a history of lactation (Table 2) but not BMI or breast size. We hypothesized that a smaller breast size and/or a lower BMI might be risk factors because the ratio breast glandular tissue/adipose tissue may be larger, resulting in a higher density of TDLUs. However, breast size and BMI did not significantly influence the presence of TDLUs behind the NAC. Hypothetically, adipose tissue is located more peripherally in the breast, whereas the concentration of breast glandular tissue centrally behind the nipple is independent of the amount of adipose breast tissue. 25 The highest number of TDLUs behind the NAC (186 TDLUs) was found in a 26-year-old woman who had one child and who had recently lactated for 18 months (results not shown). Lactation and young age were risk factors for TDLU presence in the NAC. Moreover, this specific NAC was very large, with a diameter of 7.0 cm (median diameter of the NAC was 4.0; range, 1.2 to 7.0). All these factors may have contributed to this high amount of TDLUs. The next highest number of TDLUs we found was 121 in an NAC of 7.0 cm belonging to a 40-year-old patient with 2 children and a history of lactation of 3 months (results not shown).
As breast cancer risks in high-risk patients such as BRCA1/2 mutation carriers do not necessarily diminish by increasing follow-up time, the strongest evidence for oncologic safety of NSM can be retrieved by a study with a long or lifetime follow-up after risk-reducing mastectomies. The Rotterdam series recently published by Heemskerk-Gerritsen et al 7 reported no primary breast cancers after a median follow-up of 6.3 years of 424 prophylactic mastectomies. Of these, 40 were NSMs with a median follow-up of 3.3 years. As an alternative approach, we assessed the amount of glandular tissue remaining at risk for breast cancer if it would be a prophylactic NSM. Comparable amounts of TDLUs behind the NAC and skin would suggest comparable breast cancer risks after NSM and SSM. As we found significantly more TDLUs behind the NAC as compared with the SI, that conclusion does not seem applicable. On the contrary, our results show that TDLU density is higher behind the NAC than behind the SI and that sparing the NAC hypothetically may be less safe than sparing only the skin envelope. However, the clinical relevance of these differences in TDLUs is unknown and must be placed into perspective for various reasons. First, it is unclear how many TDLUs the female breast gland comprises in total. Breast gland development and amounts of TDLUs may vary broadly interindividually.
The amounts of TDLUs we found behind NAC and SI are absolute, but their proportion to the total number of TDLUs removed during NSM is unknown. Concerning pathologic measurements, the quantity of TDLUs may be observer dependent. The 2 involved breast pathologists participating in this study (C.H.M.v.D. and P.J.W.) obtained consensus on TDLU quantity measurement and specification of TDLU location. Second, in this study SIs were examined, representing only part of the skin fold. This was an important weakness of our study. Because of the pyramid-shaped breast gland TDLU density may decrease more peripherally in the skin fold. However, the total area of the spared skin fold, including the periareolar skin, is up to a few times larger than the SI we excised (with a median diameter of 4.0 cm) and therefore is likely to contain more TDLUs than we found in the SI. This may assume that the difference in the remaining TDLUs between the NAC and skin is actually lesser than that found by us. Third, primary breast cancers occasionally do occur after prophylactic NSM (and SSM) but are mostly located in the axillary tail or in the upper-outer quadrant of the breast and very rarely in the NAC. In the rare event of a developing malignancy after NSM, a superficially located tumor of the skin or NAC combined with closely underlying breast prosthesis might be easily detectable at physical examination, contrasting tumors of the axilla. During mastectomies it is not always easy to grossly identify the lateral edge of the breast gland, and therefore glandular tissue may remain near and in the axilla. 26, 27 Sacchini et al 28 prophylactic NSMs described no new breast cancers after a mean follow-up of 22 months. Unfortunately, the BRCA1/2 mutation status in these series was unknown or not reported. Studies reporting prophylactic NSM in BRCA1/2 mutation carriers are scarce, and an overview is given in Table 3 . In summary, in 8 studies containing a total of 232 prophylactic NSMs in BRCA1/2 mutation carriers with a mean follow-up ranging between 10 and 63 months, no primary breast cancers were found.
As breast cancer incidences after NSM and SSM are very low, studies not only with long follow-up but also with a large study population are needed to possibly find a significant difference in risk reduction between NSM and SSM. Furthermore, very few studies have assessed and reported the superiority of NSM in cosmetic outcome and the quality of life as compared with SSM combined with nipple reconstruction. 12 Therefore, more studies are warranted to compare patient-reported outcomes after both procedures. Important strengths of our study concern the clinical applicability of the results because of in vivo dissection of NAC and SI by experienced breast surgeons. In addition, breast pathologists had consensus about quantitation of TDLUs. Finally, our paired analysis corrected for patientrelated influences of breast gland development.
In summary, it is important that physicians and patients opting for NSM are aware that NACs may harbor risk for developing breast cancer, albeit very small. However, this may also apply to the spared skin and possibly even more for the lateral quadrants and the axillary tail. To obtain quantification of additional breast cancer risk after NSM for prophylactic indications as compared with SSM, large studies with long follow-up are warranted.
